Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus 131I-MIBG in paediatric relapsed or progressive neuroblastoma
2007-007974-45Phase 2Active
- Sponsor
- AMC Health
- Start
- Dec 2008
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and Iobenguane I-131 in neuroblastoma (2 arms), sponsored by AMC Health. Primary endpoints: Objective response rate in MIBG-naive stratum and Objective response rate in MIBG-pretreated stratum. Started Dec 2008; status: active.
02
Drugs
gemcitabineIobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2007-007974-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007974-45.